Bupivacaine hydrochloride 0.5% (marcaine, pfizer) (DrugBank: Bupivacaine)
8 diseases告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
46 | 悪性関節リウマチ | 1 |
51 | 全身性強皮症 | 0 |
53 | シェーグレン症候群 | 0 |
70 | 広範脊柱管狭窄症 | 0 |
96 | クローン病 | 0 |
168 | エーラス・ダンロス症候群 | 0 |
226 | 間質性膀胱炎(ハンナ型) | 0 |
298 | 遺伝性膵炎 | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04361513 (ClinicalTrials.gov) | April 15, 2020 | 22/4/2020 | Genicular Nerve Block in Rheuamtoid Arthritis | Genicular Nerve Block in Rheumatoid Arthritis: a Prospective Randomized Clinical Trial | Pain;Joint Function Disorder;Inflammation | Drug: Bupivacaine hydrochloride 0.5% (Marcaine, Pfizer);Drug: triamcinolone 40 milligrams (Kenacort, Bristol Myers Squip) | Sohag University | NULL | Completed | 18 Years | N/A | All | 64 | Phase 4 | Egypt |